Visual loss due to central serous chorioretinopathy during corticosteroid treatment for giant cell arteritis

2005 ◽  
Vol 33 (4) ◽  
pp. 437-439 ◽  
Author(s):  
Timothy Bevis ◽  
Ramakrishna Ratnakaram ◽  
M Fran Smith ◽  
M Tariq Bhatti
Keyword(s):  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Central Serous Chorioretinopathy ◽  
Visual Loss ◽  
Corticosteroid Treatment

scholarly journals Steroid Induced Central Serous Chorioretinopathy in Giant Cell Arteritis

2013 ◽  
Vol 2013 ◽  
pp. 1-3
Author(s):  
Andre Grixti ◽  
Vineeth Kumar
Keyword(s):  
Differential Diagnosis ◽  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Central Serous Chorioretinopathy ◽  
Visual Loss ◽  
Corticosteroid Treatment ◽  
High Dose ◽  
Cataract Formation ◽  
Ocular Side ◽  
Systemic Corticosteroids

Giant cell arteritis (GCA) is an ophthalmic emergency which requires early diagnosis and treatment with high dose systemic corticosteroids in order to prevent permanent visual loss. However, systemic corticosteroids have significant ocular side effects including cataract formation, raised intraocular pressure, and less commonly, central serous chorioretinopathy (CSCR). We report a case of visual loss secondary to CSCR complicating corticosteroid therapy in GCA. When assessing patients with systemic conditions such as GCA or other vasculitic process, who complain of visual loss which is getting worse on corticosteroid treatment, clinicians should consider other causes such as CSCR as part of the differential diagnosis. Extra caution should be exercised in such cases as increasing the dose of corticosteroids might aggravate CSCR resulting in further visual loss.

scholarly journals Biopsy findings in giant cell arteritis: relationship to baseline factors and corticosteroid treatment

2013 ◽  
Vol 42 (4) ◽  
pp. 331-332 ◽  
Author(s):  
K Jakobsson ◽  
L Jacobsson ◽  
K Warrington ◽  
EL Matteson ◽  
C Turesson
Keyword(s):  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Corticosteroid Treatment ◽  
Baseline Factors

Osteoporosis after long-term corticosteroid treatment of giant cell arteritis

1990 ◽  
Vol 227 (6) ◽  
pp. 391-395 ◽  
Author(s):  
R. ANDERSSON ◽  
Å. RUNDGREN ◽  
K. ROSENGREN ◽  
B.-Å. BENGTSSON ◽  
B.-E. MALMVALL ◽  
...  
Keyword(s):  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Corticosteroid Treatment

scholarly journals Challenges in the Diagnosis of Giant Cell Arteritis Before Visual Loss

2020 ◽  
pp. 1-5
Author(s):  
Purnima Mehta ◽  
Faaiq Hassan ◽  
Muhammed Omar Qadir ◽  
Shirish Dubey ◽  
Sergio Pagliarini ◽  
...  
Keyword(s):  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Visual Loss ◽  
Systemic Vasculitis ◽  
The Elderly ◽  
Common Type ◽  
Atypical Presentation ◽  
Delay In Diagnosis ◽  
Atypical Presentations ◽  
High Index Of Suspicion

Background: Giant cell arteritis (GCA) is the most common type of systemic vasculitis affecting the elderly. Ophthalmic presentations of GCA in particular can be difficult to identify prior to permanent visual loss occurring. Methods: Here, we present 3 challenging cases as a retrospective series to highlight the variable presentations of GCA with ophthalmic involvement, but GCA was not suspected due to atypical presentation. Results: Unfortunately, all 3 cases went on to develop visual loss in the affected eye due to a delay in diagnosis or treatment. The authors wish to highlight the challenges posed to the referring clinicians, when patients had systemic/ocular co-morbidities, which delayed the suspicion of GCA Conclusion with a Practical Point: Our cases highlight the variable presentations of this condition as well as the devastating ophthalmic implications that GCA can have. A high index of suspicion must be maintained; particularly in elderly patients with atypical presentations.

Giant cell arteritis and transient visual loss

BMJ ◽  
2009 ◽  
Vol 338 (may06 1) ◽  
pp. b1809-b1809 ◽  
Author(s):  
C. M Guly ◽  
J. A Olson
Keyword(s):  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Visual Loss ◽  
Transient Visual Loss

scholarly journals Giant cell arteritis and COVID-19: similarities and discriminators, a systematic literature review

2020 ◽  
pp. jrheum.200766 ◽  
Author(s):  
Puja Mehta ◽  
Sebastian E. Sattui ◽  
Kornelis van der Geest ◽  
Elisabeth Brouwer ◽  
Richard Conway ◽  
...  
Keyword(s):  
Platelet Count ◽  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Visual Loss ◽  
Diagnostic Error ◽  
Evidence Based ◽  
Correct Treatment ◽  
Literature Reviews ◽  
Diagnostic Confusion ◽  
Distinct Features

Objective To identify shared and distinct features of giant cell arteritis (GCA) and Coronavirus disease 2019 (COVID-19) to reduce diagnostic error that could cause delays in correct treatment. Methods Two systematic literature reviews determined the frequency of clinical features of GCA and COVID-19 in published reports. Frequencies in each disease were summarised using median and range. Results Headache was common in GCA but was also observed in COVID-19 (66% for GCA, 10% for COVID-19). Jaw claudication or visual loss (43% and 26% in GCA, respectively) were not reported in COVID-19. Both diseases featured fatigue (38% for GCA, 43% for COVID-19) and elevated inflammatory markers (CRP elevated in 100% of GCA, 66% of COVID-19), but platelet count was elevated in 47% of GCA but 4% of COVID-19. Cough and fever were commonly reported in COVID-19 and less frequently in GCA (cough, 63% for COVID-19 versus 12% for GCA; fever, 83% for COVID-19 versus 27% for GCA). Gastrointestinal upset was occasionally reported in COVID-19 (8%), rarely in GCA (4%). Lymphopenia was more common in COVID-19 than GCA (53% in COVID-19, 2% in GCA). Alteration of smell and taste been described in GCA but their frequency is unclear. Conclusion Overlapping features of GCA and COVID-19 include headache, fever, elevated CRP and cough. Jaw claudication, visual loss, platelet count and lymphocyte count may be more discriminatory. Physicians should be aware of the possibility of diagnostic confusion. We have designed a simple checklist to aid evidence-based evaluation of patients with suspected GCA.

scholarly journals Giant Cell Arteritis: Visual Loss Is Our Major Concern

2016 ◽  
Vol 43 (8) ◽  
pp. 1458-1461 ◽  
Author(s):  
MIGUEL A. GONZALEZ-GAY ◽  
SANTOS CASTAÑEDA ◽  
JAVIER LLORCA
Keyword(s):  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Visual Loss

–463 G/A myeloperoxidase promoter polymorphism in giant cell arteritis

2007 ◽  
Vol 67 (4) ◽  
pp. 485-488 ◽  
Author(s):  
C Salvarani ◽  
B Casali ◽  
E Farnetti ◽  
N Pipitone ◽  
D Nicoli ◽  
...  
Keyword(s):  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Clinical Features ◽  
Polymyalgia Rheumatica ◽  
Visual Loss ◽  
Geographic Area ◽  
Population Based ◽  
Promoter Polymorphism ◽  
Reggio Emilia ◽  
Cerebrovascular Accidents

Objective:To investigate potential associations between–463 G/A myeloperoxidase (MPO) promoter polymorphism and susceptibility to, and clinical features of giant cell arteritis (GCA).Methods:A total of 156 patients with biopsy-proven GCA who were residents of Reggio Emilia, Italy, and 235 population-based controls from the same geographic area were genotyped for–463 G/A promoter polymorphism of the MPO gene by molecular methods. The patients were subgrouped according to the presence or absence of polymyalgia rheumatica and severe ischaemic complications (visual loss and/or cerebrovascular accidents).Results:The distribution of the MPO-G/A genotype differed significantly between patients with GCA and the controls (pcorr = 0.003). Allele G was significantly more frequent in patients with GCA than in the controls (pcorr = 0.0002, OR 2.0, 95% CI 1.4 to 2.9). Homozygosity for the G allele was significantly more frequent in patients with GCA than in controls (pcorr = 0.0002, OR 2.2, 95% CI 1.4 to 3.4). No significant associations were found when patients with GCA with and without polymyalgia rheumatica or with and without severe ischaemic complications were compared.Conclusions:Our findings show that the–463 G/A promoter polymorphism of the MPO gene is associated with GCA susceptibility and support a role for MPO in the pathophysiology of GCA.

Sign in / Sign up

Export Citation Format

Share Document